The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Sarepta Therapeutics, Inc.

  • SRPT
  • NASDAQ
  • Consumer Products
  • Latest 22.53
  • Currency US$
  • Change -0.41
  • Percent Change -1.787 %
  • Volume 525,352
  • Thu Sep 18, 2014 12:15 PM EDT NASDAQ data delayed 15 minutes.
  • Open 23.06
  • Previous Close 22.94
  • High 23.06
  • Low 22.31
  • Bidx1 15.14
  • Askx1 23.06
  • 52-week High10/07 55.61
  • 52-week Low11/13 12.12
  • Beta -0.095
  • Market Cap 851.18M
  • EPS -3.07
  • P/E
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $15,840,000
  • Earnings $-98,170,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $49,100,000
  • Current Ratio 6.61

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $275,380,000
  • Liabilities $46,420,000
  • Liabilities-to-Equity Ratio 0.20

Price Ratios

  • Price to Sales 53.74
  • Price to Book 3.72
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Aug 7 $-0.78 Nov 11 $-0.94
Surprises Aug 7 8.97% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Sep 19, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.

Related Securities
Symbol Type Latest % Chg

Officers

  • William Goolsbee Chairman of the Board
  • Christopher Garabedian President; Chief Executive Off
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

215 FIRST STREET SUITE 415
CAMBRIDGE, MA
02142

Phone: (617)-274-4000
Fax: (425)-3545038

investors@sarepta.com
www.sareptatherapeutics.com

Ideas & Discussion

Live Discussion of SRPT on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.